Drugs / PERT-IJS
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06038539 | Jan → Dec 2025 | HER2 positive breast carcinoma | Biocon Biologics UK Ltd | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PERT-IJS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06038539 ↗ |
| Modality | Monoclonal antibody | “PERT-IJS is a monoclonal antibody” NCT06038539 ↗ |
| Route | Intravenous | “420 mg administered as an IV infusion” NCT06038539 ↗ |